What if… we could unlock the full power of precision medicine?

Transforming Treatments Means Transforming Lives

We are pioneers of silicon-based Bio-Courier® technology, an advanced and highly tailored approach that advances drug delivery into the age of precision medicine. Built upon a decade of research and patented technological innovation, our platform is changing the way therapeutic molecules target disease helping to make tomorrow’s medicines a reality.

Company

SiSaf is a commercial stage biopharmaceutical company. Our pipeline of transformative Gene Therapies, accelerated New Therapeutic Entities and advanced Personal Care development candidates create multiple blockbuster opportunities.

Pipeline

Team

Led by an authority in the delivery of nucleic acid and silicon innovation, Dr Suzanne Saffie-Siebert, our expert team is focused on driving clinical and commercial success.

Meet The Team

Technology

SiSaf’s Bio-Courier platform leverages the unique properties of the worlds 1st bioabsorbable silicon (14Si) to overcome the limitations of current drug technologies.

More

Why Sisaf?

We’re creating multiple block-buster product opportunities with the safe and efficient non-viral delivery of gene therapy and a faster, lower risk approach to drug development.

More

News

Non-invasive ocular siRNA delivery induces effective gene silencing in corneal epithelium

More

SiSaf announces licencing agreement to develop gene therapy for rare bone disease

More

SiSaf Makes Its Bio-Courier® Technology Available for COVID-19 Vaccine Research

More

SiSaf Establishes Strategic Partnership with Avellino Labs

More

SiSaf Strengthens it’s Leadership Team

More

SiSaf Ltd Appoints Former Oxford BioMedica Executive

More

Croda Invests in SiSaf’s Novel Bio-Courier Technology

More

UK based biopharmaceutical company SiSaf closes $4.3 million interim funding round

More

SiSaf’s Chairwoman and Chief Executive Officer, Suzanne Saffie-Siebert featured on BBC Radio 4’s ‘In Business’

More

Next-gen silicon nanotechnology drug delivery company SiSaf raises $3.5 million in Series A Funding

More

Silicon Valley Investors Lead Funding Round in SiSaf

More

SiSaf Releases latest Clinical Data Showing a 95% Reduction in Acne

More